Cargando…

Insights into the fate of the N-terminal amyloidogenic polypeptide of ApoA-I in cultured target cells

Apolipoprotein A-I (ApoA-I) is an extracellular lipid acceptor, whose role in cholesterol efflux and high-density lipoprotein formation is mediated by ATP-binding cassette transporter A1 (ABCA1). Nevertheless, some ApoA-I variants are associated to systemic forms of amyloidosis, characterized by ext...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arciello, Angela, De Marco, Nadia, Del Giudice, Rita, Guglielmi, Fulvio, Pucci, Piero, Relini, Annalisa, Monti, Daria Maria, Piccoli, Renata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2011
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373434/ https://www.ncbi.nlm.nih.gov/pubmed/21306558 http://dx.doi.org/10.1111/j.1582-4934.2011.01271.x

Ejemplares similares

The Apparent Organ-Specificity of Amyloidogenic ApoA-I Variants Is Linked to Tissue-Specific Extracellular Matrix Components
por: Del Giudice, Rita, et al.
Publicado: (2022)

Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux
por: Nilsson, Oktawia, et al.
Publicado: (2020)

Misfolding of Amyloidogenic Proteins and Their Interactions with Membranes
por: Relini, Annalisa, et al.
Publicado: (2013)

Amyloidogenic variant of apolipoprotein A-I elicits cellular stress by attenuating the protective activity of angiogenin
por: Del Giudice, R, et al.
Publicado: (2014)

Autophagy Alteration in ApoA-I Related Systemic Amyloidosis
por: Del Giudice, Rita, et al.
Publicado: (2022)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

Effect of apoA-I PEGylation on the Biological Fate of Biomimetic High-Density Lipoproteins
por: Pedersbæk, Dennis, et al.
Publicado: (2020)

Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
por: Ma, Cheng, et al.
Publicado: (2015)

Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015)

SIDT2 Associates with Apolipoprotein A1 (ApoA1) and Facilitates ApoA1 Secretion in Hepatocytes
por: Sampieri, Alicia, et al.
Publicado: (2023)

ApoA-1 in Diabetes: Damaged Goods
por: Ory, Daniel S., et al.
Publicado: (2010)

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007)

Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy
por: Camacho, Jessica, et al.
Publicado: (2019)

The unsolved mystery of apoA-I recycling in adipocyte
por: Wang, Shuai, et al.
Publicado: (2016)

LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea
por: Flores, Rhonda, et al.
Publicado: (2019)

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
por: Walldius, Göran, et al.
Publicado: (2021)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016)

Effects of Individual Amino Acids on PPARα Transactivation, mTORC1 Activation, ApoA-I Transcription and pro-ApoA-I Secretion
por: Tayyeb, Jehad Z., et al.
Publicado: (2022)

Synchrotron radiation circular dichroism spectroscopy reveals structural divergences in HDL-bound apoA-I variants
por: Giudice, Rita Del, et al.
Publicado: (2017)

Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes
por: Bencharif, Karima, et al.
Publicado: (2010)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
por: Gorshkova, Irina N., et al.
Publicado: (2022)

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013)

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
por: Georgila, Konstantina, et al.
Publicado: (2019)

Clinical ApoA‐IV amyloid is associated with fibrillogenic signal sequence
por: Canetti, Diana, et al.
Publicado: (2021)

ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity()
por: Lu, Min, et al.
Publicado: (2011)

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
por: Valanti, Eftaxia-Konstantina, et al.
Publicado: (2018)

Crystallization of ApoA1 and ApoE4 nanolipoprotein particles and initial XFEL-based structural studies
por: Shelby, M.L., et al.
Publicado: (2020)

Elevated ApoB/apoA-1 is Associated with in-Hospital Mortality in Elderly Patients with Acute Myocardial Infarction
por: Chen, Yan, et al.
Publicado: (2023)

Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome
por: Ng, Theodore W. K., et al.
Publicado: (2009)

ApoA-I-Mediated Lipoprotein Remodeling Monitored with a Fluorescent Phospholipid
por: Neufeld, Edward B., et al.
Publicado: (2019)

Association of serum apoA-I with in-stent restenosis in coronary heart disease
por: Wang, Xin, et al.
Publicado: (2022)

Structural Similarities and Differences between Amyloidogenic and Non-Amyloidogenic Islet Amyloid Polypeptide (IAPP) Sequences and Implications for the Dual Physiological and Pathological Activities of These Peptides
por: Wu, Chun, et al.
Publicado: (2013)

ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator
por: Kido, Toshimi, et al.
Publicado: (2017)

Prognosis evaluation of universal acute coronary syndrome: the interplay between SYNTAX score and ApoB/ApoA1
por: Wang, Xiaotong, et al.
Publicado: (2020)

Association of oxidized ApoB and oxidized ApoA-I with high-risk coronary plaque features in cardiovascular disease
por: Sorokin, Alexander V., et al.
Publicado: (2023)

Comparison of the structure-function properties of wild-type human apoA-V and a C-terminal truncation associated with elevated plasma triglycerides
por: Stankov, Sylvia, et al.
Publicado: (2023)

APOA1-75 G to A Substitution Associated with Severe Forms of CAD, Lower Levels of HDL and apoA-I among Northern Indians
por: Chhabra, S., et al.
Publicado: (2005)

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
por: McLure, Kevin G., et al.
Publicado: (2013)

ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV
por: Daskou, Maria, et al.
Publicado: (2022)

ApoB/ApoA-1 Ratio as a Novel Prognostic Predictor in Patients With Primary Small Cell Carcinoma of the Esophagus
por: Chen, Hao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g5eo2dsjm4io80ht1e32kkbdqs